ITGR Quote, Financials, Valuation and Earnings

AngioDynamics has a net margin of -5.14% compared to Integer Holdings's net margin of -6.12%. Integer Holdings's return on equity of 4.85% beat AngioDynamics's return on equity of -20.83%.

Integer Holdings has a consensus price target of $148.75, signalling upside risk potential of 24.59%. On the other hand AngioDynamics has an analysts' consensus of $15.67 which suggests that it could grow by 52.7%. Given that AngioDynamics has higher upside potential than Integer Holdings, analysts believe AngioDynamics is more attractive than Integer Holdings.

Integer Holdings has a beta of 1.030, which suggesting that the stock is 3.045% more volatile than S&P 500. In comparison AngioDynamics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.778%.

Integer Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AngioDynamics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integer Holdings pays -- of its earnings as a dividend. AngioDynamics pays out -- of its earnings as a dividend.

Integer Holdings quarterly revenues are $437.4M, which are larger than AngioDynamics quarterly revenues of $72M. Integer Holdings's net income of -$22.5M is lower than AngioDynamics's net income of -$4.4M. Notably, Integer Holdings's price-to-earnings ratio is 56.58x while AngioDynamics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integer Holdings is 2.41x versus 1.47x for AngioDynamics. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -5.14% compared to Integer Holdings's net margin of 14.45%. Integer Holdings's return on equity of 4.85% beat Boston Scientific's return on equity of 9.57%.

Integer Holdings has a consensus price target of $148.75, signalling upside risk potential of 24.59%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 11.92%. Given that Integer Holdings has higher upside potential than Boston Scientific, analysts believe Integer Holdings is more attractive than Boston Scientific.

Integer Holdings has a beta of 1.030, which suggesting that the stock is 3.045% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Integer Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integer Holdings pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Integer Holdings quarterly revenues are $437.4M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Integer Holdings's net income of -$22.5M is lower than Boston Scientific's net income of $674M. Notably, Integer Holdings's price-to-earnings ratio is 56.58x while Boston Scientific's PE ratio is 76.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integer Holdings is 2.41x versus 8.86x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Enovis has a net margin of -5.14% compared to Integer Holdings's net margin of -10.02%. Integer Holdings's return on equity of 4.85% beat Enovis's return on equity of -26.77%.

Integer Holdings has a consensus price target of $148.75, signalling upside risk potential of 24.59%. On the other hand Enovis has an analysts' consensus of $56.50 which suggests that it could grow by 73.47%. Given that Enovis has higher upside potential than Integer Holdings, analysts believe Enovis is more attractive than Integer Holdings.

Integer Holdings has a beta of 1.030, which suggesting that the stock is 3.045% more volatile than S&P 500. In comparison Enovis has a beta of 1.583, suggesting its more volatile than the S&P 500 by 58.325%.

Integer Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integer Holdings pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

Integer Holdings quarterly revenues are $437.4M, which are smaller than Enovis quarterly revenues of $558.8M. Integer Holdings's net income of -$22.5M is higher than Enovis's net income of -$56M. Notably, Integer Holdings's price-to-earnings ratio is 56.58x while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integer Holdings is 2.41x versus 0.85x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -5.14% compared to Integer Holdings's net margin of 12.62%. Integer Holdings's return on equity of 4.85% beat Globus Medical's return on equity of 4.59%.

Integer Holdings has a consensus price target of $148.75, signalling upside risk potential of 24.59%. On the other hand Globus Medical has an analysts' consensus of $85.17 which suggests that it could grow by 43.84%. Given that Globus Medical has higher upside potential than Integer Holdings, analysts believe Globus Medical is more attractive than Integer Holdings.

Integer Holdings has a beta of 1.030, which suggesting that the stock is 3.045% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.371%.

Integer Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integer Holdings pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Integer Holdings quarterly revenues are $437.4M, which are smaller than Globus Medical quarterly revenues of $598.1M. Integer Holdings's net income of -$22.5M is lower than Globus Medical's net income of $75.5M. Notably, Integer Holdings's price-to-earnings ratio is 56.58x while Globus Medical's PE ratio is 44.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integer Holdings is 2.41x versus 3.27x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.